Interaktionen zwischen Östrogenrezeptor- und Rezeptor-Tyrosinkinase-Signaltransduktion: Implikationen für die Therapie des Mammakarzinoms

Zusammenfassung

Das Wachstum von malignen Tumoren der Brustdrüse kann durch Östrogene und Wachstumsfaktoren reguliert werden. Die zelluläre Reaktion auf diese Stimuli wird durch Östrogenrezeptoren und Rezeptor-Tyrosinkinasen vermittelt. Diese beiden Signalwege wurden bis vor kurzer Zeit nur isoliert betrachtet, allerdings häufen sich Hinweise darauf, dass ihre Interaktion nicht die Ausnahme, sondern ein Prinzip ihrer Wirkung ist. Ein Beispiel für die mögliche klinische Bedeutung dieser Wechselwirkung ist der Einfluss einer HER-2/neu-Überexpression auf die Wirkung des Antiöstrogens Tamoxifen bei der Behandlung von Patientinnen mit Mammakarzinom. Umgekehrt gibt es Hinweise darauf, dass die „nichtgenomischen“ Effekte von Östradiol die Wirksamkeit von antitumoralen Substanzen hemmen können, die gegen die Rezeptor-Tyrosinkinase-Signaltransduktion gerichtet sind. In dieser Übersicht werden neue Erkenntnisse über die molekularen Mechanismen der Interaktion zwischen zellulärer Östradiolantwort und Wachstumsfaktor-Signaltransduktion ebenso dargestellt wie deren Bedeutung für die Wirkung antitumoraler Substanzen, die in der Therapie des Mammakarzinoms eingesetzt werden.

Abstract

Growth of breast cancer cells is regulated by estrogens and growth factors. Cellular response to these stimuli is mediated by estrogen receptors and receptor tyrosine kinases. Originally both pathways were considered as independent signaling mechanisms. Now there is evidence for a broad cross-talk between these signal transduction pathways. The relationship between overexpression of HER-2/neu receptor tyrosine kinase and tamoxifen resistance is a possible example for the clinical relevance of this signaling cross-talk. Additionally, nongenomic effects of estrogens are able to interfere with the action of antitumoral substances directed against dysregulated receptor tyrosine kinases by activation of kinases downstream the receptor. Novel insights into the molecular mechanisms underlying the cross-talk between both signaling mechanisms and their impact on the efficacy of antitumoral substances directed against these pathways are reviewed.

Schlüsselwörter

Östrogene - Östrogenrezeptoren - Wachstumsfaktoren - Rezeptor-Tyrosinkinasen - Antiöstrogene

Key words

Estrogens - estrogen receptor - growth factor - receptor tyrosine kinases - antiestrogens

Literatur

• 1 Horwitz K B, Freidenberg G R. Growth inhibition and increase of insulin receptors in antiestrogen-resistant T47DCO human breast cancer cells by progestins: implications for endocrine therapies.  Cancer Res. 1985;  45 167-173
• 2 Lange C A, Richer J K, Horwitz K B. et al . Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals.  Mol Endocrinol. 1999;  13 829-836
• 3 Lippman M E, Dickson R B. Mechanisms of normal and malignant breast epithelial growth regulation.  J Steroid Biochem. 1989;  34 107-121
• 4 Suo Z, Risberg B, Karlsson M G, Villman K. et al . The expression of EGFR family ligands in breast carcinomas.  Int J Surg Pathol. 2002;  10 91-99
• 5 Chrysogelos S A, Dickson R B. EGF receptor expression, regulation, and function in breast cancer.  Breast Cancer Res Treat. 1994;  29 29-40
• 6 Zwick E, Bange J, Ullrich A. et al . Receptor tyrosine kinase signalling as a target for cancer intervention strategies.  Endocr Relat Cancer. 2001;  8 161-173
• 7 Webb P, Nguyen P, Valentine C, Kushner P. et al . The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions.  Mol Endocrinology. 1999;  13 1673-1685
• 8 Kato S, Endoh H, Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.  Science. 1995;  270 1491-1494
• 9 Beato M. Gene regulation by steroid hormones.  Cell. 1989;  56 335-344
• 10 Gustafsson J-Å. Estrogen receptor beta - a new dimension in estrogen mechanism of action.  J Endocrinol. 1999;  163 379-383
• 11 Mc Donnel D P, Nawaz Z, O'Malley B W. In situ distinction between steroid receptor binding and transactivation at a target gene.  Mol Cell Biol. 1991;  11 4350-4355
• 12 Charpentier A H, Bednarek A K, Daniel R L. et al . Effects of estrogen on global gene expression: identification of novel targets of estrogen action.  Cancer Res. 2000;  60 5977-5983
• 13 Mukku V R, Stancel G M. Regulation of epidermal growth factor receptor by estrogen.  J Biol Chem. 1985;  260 9820-9824
• 14 Lee A V, Jackson J G, Gooch J L. et al . Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.  Mol Endocrinol. 1999;  13 787-796
• 15 Knabbe C, Lippman M E, Wakefield L M. et al . Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells.  Cell. 1987;  48 417-428
• 16 Huynh H, Yang X, Pollak M. et al . Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells.  Biol Chem. 1996;  271 1016-1021
• 17 Mathieu M, Vignon F, Capony F. et al . Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: a receptor saturation mechanism to increase the secretion of lysosomal proenzymes.  Mol Endocrinol. 1991;  5 815-822
• 18 Endoh H, Sasaki H, Maruyama K. et al . Rapid activation of MAP kinase by estrogen in the bone cell line.  Biochem Biophys Res Commun. 1997;  235 99-102
• 19 Migliaccio A, Di Domencio M, Nola E. et al . Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.  EMBO J. 1996;  15 1292-1300
• 20 Toran-Allerand C D, Singh M, Setalo Jr G. et al . Novel mechanisms of estrogen action in the brain: new players in an old story.  Front Neuroendocrinol. 1999;  20 97-121
• 21 Castoria G, Barone M V, Di-Domenico M. et al . Non-transcriptional action of oestradiol and progestin triggers DNA synthesis.  EMBO J. 1999;  18 2500-2510
• 22 Singh M, Setalo Jr G, Guan X, Frail D E. Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-alpha knock-out mice.  J Neurosci. 2000;  20 1694-1700
• 23 Kahlert S, Nuedling S, van Eickels M. et al . Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway.  J Biol Chem. 2000;  275 18447-18453
• 24 Simoncini T, Hafezi-Moghadam A, Brazil D P. et al . Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase.  Nature. 2000;  407 538-541
• 25 Webb P, Lopez G N, Uht R M. et al . Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens.  Mol Endocrinol. 1995;  9 443-456
• 26 Norfleet A M, Thomas M L, Gametchu B. et al . Estrogen receptor-alpha detected on the plasma membrane of aldehyde-fixed GH3/B6/F10 rat pituitary tumor cells by enzyme-linked immunocytochemistry.  Endocrinology. 1999;  140 3805-3814
• 27 Monje P, Boland R. Characterization of membrane estrogen binding proteins from rabbit uterus.  Mol Cell Endocrinol. 1999;  147 75-84
• 28 Razandi M, Pedram A, Greene G L. et al . Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells.  Mol Endocrinol. 1999;  13 307-319
• 29 Filardo E J, Quinn J A, Bland K I. et al . Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.  Mol Endocrinol. 2000;  14 1649-1660
• 30 Filardo E J, Quinn J A, Frackelton A R, Bland K I. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.  Mol Endocrinol. 2002;  16 70-84
• 31 Gehm B G, McAndrews J M, Jameson J L. et al . EGF activates highly selective estrogen-responsive reporter plasmids by an ER-independent pathway.  Mol Cell Endocrinol. 2000;  159 53-62
• 32 Vignon F, Bouton M M, Rochefort H. et al . Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens.  Biochem Biophys Res Commun. 1987;  146 1502-1508
• 33 Curtis S W, Washburn T, Sewall C. et al . Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor.  PNAS USA. 1996;  39 12626-12630
• 34 Smith C L. Cross-talk between peptide growth factor and estrogen receptor signaling pathways.  Biol Reprod. 1998;  58 627-632
• 35 El-Tanani M K, Green C D. Two separate mechanisms for ligand-independent activation of the estrogen receptor.  Mol Endocrinology. 1997;  11 928-937
• 36 Tremblay A, Tremblay G B, Labrie F, Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1.  Mol Cell. 1999;  3 513-519
• 37 Joel P B, Traish A M, Lannigan D A. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase.  J Biol Chem. 1998;  273 13317-13323
• 38 Feng W, Webb P, Nguyen P. et al . Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway.  Mol Endocrinol. 2001;  15 32-45
• 39 Joel P B, Smith J, Sturgill T W. et al . pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167.  Mol Cell Biol. 1998;  18 1978-1984
• 40 Lee H, Jiang F, Wang Q. et al . MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells.  Mol Endocrinol. 2000;  14 1882-1896
• 41 Planas Silva M, Donaher J L, Weinberg R A. Functional activity of ectopically expressed estrogen receptor is not sufficient for estrogen-mediated cyclin D1 expression.  Cancer Res. 1999;  59 4788-4792
• 42 Dufourny B, Alblas J, van Teefelen H A. et al . Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase.  J Biol Chem. 1997;  272 31163-31171
• 43 Zwijsen R M, Wientjens E, Klompmaker R. et al . CDK-independent activation of estrogen receptor by cyclin D1.  Cell. 1997;  88 405-415
• 44 Neuman E, Ladha M H, Lin N. et al . Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.  Mol Cell Biol. 1997;  17 5338-5347
• 45 Zwijsen R M, Buckle R S, Hijmans E M. et al . Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1.  Genes Dev. 1998;  12 3488-3498
• 46 Mc Mahon C, Suthphongchai T, Di Renzo J. et al . P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor.  PNAS USA. 1999;  96 5382-5387
• 47 Johnston S R, Haynes B P, Smith I E. et al . Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.  Lancet. 1993;  342 1521-1522
• 48 Scott G K, Kushner P, Vigne J L, Benz C C. Truncated forms of DNA-binding estrogen receptors in human breast cancer.  Clin Invest. 1991;  88 700-706
• 49 Katzenellenbogen B S, Montano M M, Le Goff P. Antiestrogens: mechanisms and actions in target cells.  J Steroid Biochem Molec Biol. 1995;  53 387-393
• 50 Revillion F, Bonneterre J, Peyrat J P. et al . ERBB2 oncogene in human breast cancer and its clinical significance.  Eur J Cancer. 1998;  34 791-808
• 51 De Laurentiis M, Arpino G, Massarelli E. Metaanalysis of the interaction between Her2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC).  Proc Am Soc Clin Oncol. 2000;  19 300
• 52 Adjuvant Therapy for Breast Cancer . .  NIH Consensus Statement. 2000;  17 1-23
• 53 Wright C, Nicholson S, Angus B. et al . Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.  Br J Cancer. 1992;  65 118-121
• 54 Borg A, Baldetorp B, Fernö M. et al . ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.  Cancer Lett. 1994;  81 137-144
• 55 Leitzel K, Teramoto Y, Konrad K. et al . Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.  J Clin Oncol. 1995;  13 1129-1135
• 56 Carlomagno C, Perrone F, Gallo C. et al . c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.  J Clin Oncol. 1996;  14 2702-2708
• 57 Yamauchi H, O'Neill A, Gelman R. et al . Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.  J Clin Oncol. 1997;  15 2518-2525
• 58 Elledge R M, Green S, Ciocca D. et al . HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.  Clin Cancer Res. 1998;  4 7-12
• 59 Houston S J, Plunkett T A, Barnes D M. et al . Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer.  Br J Cancer. 1999;  79 1220-1226
• 60 Berry D A, Muss H B, Thor A D. et al . HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.  J Clin Oncol. 2000;  18 3471-3479
• 61 Knoop A S, Bentzen S M, Nielsen M M. et al . Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.  J Clin Oncol. 2001;  19 3376-3384
• 62 Pietras R J, Arboleda J, Reese D M. et al . HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.  Oncogene. 1995;  10 2435-2446
• 63 Nicholson R I, Gee J M. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.  Br J Cancer. 2000;  82 501-513
• 64 Kurokawa H, Lenferink A EG, Simpson J F. et al . Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.  Cancer Res. 2000;  60 5887-5894
• 65 Campbell R A, Bhat-Nakshatri P, Patel N M. et al . Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.  J Biol Chem. 2001;  276 9817-9824
• 66 McCLelland R, Barrow A, Madden T A. et al . Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex).  Endocrinology. 2001;  142 2776-2778
• 67 Shim W S, Conaway M, Masamura S. et al . Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo.  Endocrinology. 2000;  141 396-405
• 68 Coutts A S, Murphy L C. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells.  Cancer Res. 1998;  58 4071-4074
• 69 Larsen S S, Egeblad M, Jaattela M. et al . Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.  Breast Cancer Res Treat. 1999;  58 41-56
• 70 Oesterreich S, Zhang P, Guler R L. et al . Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth.  Cancer Res. 2001;  61 5771-5777
• 71 Treeck O, Diedrich K, Ortmann O. Activation of extracellular signal-regulated kinase by estradiol impairs the inhibitory effect of trastuzumab on HER2 signaling in endometrial adenocarcinoma cell lines.  Eur J Cancer. ;  in press
• 72 Gee J M, Hutcheson I R, Knowlden J M. et al . The EGFR-selective tyrosine kinase inhibitor ZD1839 (Iressa) is an effective inhibitor of Tamoxifen-resistant breast cancer growth.  Proc Am Soc Clin Oncol. 2001;  20 282
• 73 Smaill J B, Rewcastle G W, Loo J A. et al . Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3, 2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.  J Med Chem. 2000;  43 1380-1397
• 74 Sherwood V, Bridges A J, Denny W A. et al . Specific, irreversible inactivation of the epidermal growth factor receptor and ErB2 by a new class of tyrosine kinase inhibitor.  Proc Am Assoc Cancer Res. 1999;  40 723
• 75 Baselga J, Averbuch S D. ZD1839 (‘Iressa') as an anticancer agent.  Drugs. 2000;  60 33-40
• 76 Moulder S L, Yakes F M, Bianco R. et al . Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.  Cancer Res. 2001;  24 8887-8895
• 77 Moyer J D, Barbacci E G, Iwata K K. et al . Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase.  Cancer Res. 1997;  57 4838-4848
• 78 Torance C J, Jackson P E, Montgomery E. et al . Combinatorial chemoprevention of intestinal neoplasia.  Nat Med. 2000;  6 1024-1028
• 79 Bruns C J, Solorzano C C, Harbison M T. et al . Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.  Cancer Res. 2000;  60 2926-2935
• 80 Xia W, Mullin R, Keith B. et al . GW2016, a dual inhibitor of erB-2 and EGFR tyrosine kinases: Effects on receptor tyrosine autophosphorylation, downstream signaling intermediaries, and in vivo anti-tumor activity.  Proc Am Assoc Cancer Res. 2001;  42 3635
• 81 Huober J, Wagner U, Wallwiener D. Der Stellenwert von Aromatasehemmern in der dritten Generation in der endokrinen Therapie des Mammakarzinoms - Zeit zum Umdenken?.  Geburtsh Frauenheilk. 2002;  62 15-21
• 82 Wolf C. et al . GENARI - Ein Studienkonzept zur Prüfung von Verträglichkeit, Wirksamkeit und Nutzen einer chemoendokrinen präoperativen Behandlung mit Exemestan.  Geburtsh Frauenheilk. 2002;  62 333-338
• 83 Ellis M J, Coop A, Singh B. et al . Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.  J Clin Oncol. 2001;  19 3808-3816